Annunziata S, Laudicella R, Caobelli F, Pizzuto DA, Aimn Working Group Y. Clinical Value of PET/CT in Staging Melanoma and Potential New Radiotracers.
Curr Radiopharm 2020;
13:6-13. [PMID:
31749438 DOI:
10.2174/1874471012666191015094620]
[Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Revised: 02/02/2019] [Accepted: 07/17/2019] [Indexed: 12/24/2022]
Abstract
BACKGROUND
18F-FDG PET/CT has been suggested as an effective tool to stage patients affected by melanoma. In the latest years, new radiopharmaceuticals have been proposed and the use of hybrid PET/ceCT has emerged.
OBJECTIVE
To review recent evidence on the role of PET/CT in melanoma staging as well as its potential for future developments.
METHODS
A comprehensive computer literature search of PubMed/MEDLINE was carried out to find relevant published articles concerning the feasibility of PET/CT in patients with malignant melanoma.
RESULTS
Some recent studies about potentials and limitations of 18F-FDG PET/CT in staging melanoma, new PET radiotracers beyond 18F-FDG and application of hybrid PET/ceCT have been reviewed and discussed.
CONCLUSION
PET/CT plays an important role in the staging workup of patients affected by melanoma. New radiopharmaceuticals and hybrid PET/ceCT could improve the potential of this diagnostic tool in this field.
Collapse